JP2008503498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503498A5 JP2008503498A5 JP2007516827A JP2007516827A JP2008503498A5 JP 2008503498 A5 JP2008503498 A5 JP 2008503498A5 JP 2007516827 A JP2007516827 A JP 2007516827A JP 2007516827 A JP2007516827 A JP 2007516827A JP 2008503498 A5 JP2008503498 A5 JP 2008503498A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- tuaas
- protein
- antigen
- ssx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58096904P | 2004-06-17 | 2004-06-17 | |
| PCT/US2005/021836 WO2006002114A2 (en) | 2004-06-17 | 2005-06-17 | Tumor-associated antigen profiles in cancer diagnostics and immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503498A JP2008503498A (ja) | 2008-02-07 |
| JP2008503498A5 true JP2008503498A5 (https=) | 2008-08-07 |
Family
ID=35478743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516827A Pending JP2008503498A (ja) | 2004-06-17 | 2005-06-17 | 癌の診断及び免疫療法における腫瘍関連抗原プロファイル |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1782070B1 (https=) |
| JP (1) | JP2008503498A (https=) |
| AT (1) | ATE480776T1 (https=) |
| AU (1) | AU2005258014B2 (https=) |
| CA (1) | CA2571070A1 (https=) |
| DE (1) | DE602005023488D1 (https=) |
| DK (1) | DK1782070T3 (https=) |
| ES (1) | ES2351995T3 (https=) |
| MX (1) | MXPA06014771A (https=) |
| WO (1) | WO2006002114A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| AU2005321898B2 (en) * | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| EP2032719A2 (en) * | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| NZ583318A (en) | 2007-07-16 | 2012-07-27 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| GB0720118D0 (en) * | 2007-10-15 | 2007-11-28 | Achour Adnane | Modified mhc class 1 binding peptides |
| WO2009068621A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Method for classifying cancer patients as responder or non-responder to immunotherapy |
| SG187517A1 (en) | 2008-01-31 | 2013-02-28 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| AU2009215503B2 (en) * | 2008-02-20 | 2014-05-08 | Arizona Cancer Therapeutics, Llc | Use of therapeutic peptides for the treatment and prevention of cancer |
| GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Plus Therapeutics Inc. | Devices and methods of cell capture and analysis |
| JP2013544237A (ja) | 2010-10-12 | 2013-12-12 | アリゾナ バイオメディカル リサーチ コミッション | Ｅｇｆｒベースのペプチド |
| US10066004B2 (en) | 2010-10-12 | 2018-09-04 | Arizona Cancer Therapeutics, Llc | EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3 |
| PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| US20150044224A1 (en) * | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| WO2014074785A1 (en) * | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
| PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| WO2017176946A1 (en) * | 2016-04-05 | 2017-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for targeted therapy based on single-cell stimulus perturbation response |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| US20220370586A1 (en) * | 2019-08-08 | 2022-11-24 | Cedars-Sinai Medical Center | Method of generating activated t cells for cancer therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4940670A (en) * | 1986-01-24 | 1990-07-10 | Rhodes Buck A | Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use |
| US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| DE10225139A1 (de) * | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
-
2005
- 2005-06-17 JP JP2007516827A patent/JP2008503498A/ja active Pending
- 2005-06-17 DE DE602005023488T patent/DE602005023488D1/de not_active Expired - Lifetime
- 2005-06-17 WO PCT/US2005/021836 patent/WO2006002114A2/en not_active Ceased
- 2005-06-17 CA CA002571070A patent/CA2571070A1/en not_active Abandoned
- 2005-06-17 MX MXPA06014771A patent/MXPA06014771A/es active IP Right Grant
- 2005-06-17 AT AT05766030T patent/ATE480776T1/de not_active IP Right Cessation
- 2005-06-17 DK DK05766030.0T patent/DK1782070T3/da active
- 2005-06-17 AU AU2005258014A patent/AU2005258014B2/en not_active Ceased
- 2005-06-17 EP EP05766030A patent/EP1782070B1/en not_active Revoked
- 2005-06-17 ES ES05766030T patent/ES2351995T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503498A5 (https=) | ||
| JP2008546687A5 (https=) | ||
| Nagorsen et al. | Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer | |
| Schlom | Therapeutic cancer vaccines: current status and moving forward | |
| Yamada et al. | Next‐generation peptide vaccines for advanced cancer | |
| Del Campo et al. | Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma | |
| Disis | Immune regulation of cancer | |
| Seliger et al. | HER‐2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA‐A2. 1‐restricted cytotoxic T lymphocytes | |
| Cloosen et al. | Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy | |
| Forghanifard et al. | Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development | |
| Tang et al. | Strategies used for MUC1 immunotherapy: human clinical studies | |
| Esfandiary et al. | New York esophageal squamous cell carcinoma-1 and cancer immunotherapy | |
| Faramarzi et al. | Melanoma: a prototype of cancer-testis antigen-expressing malignancies | |
| Smith et al. | Expression and immunotherapeutic targeting of the SSX family of cancer–testis antigens in prostate cancer | |
| Hale et al. | Cancer vaccines: should we be targeting patients with less aggressive disease? | |
| JP2008526760A5 (https=) | ||
| Narayanan et al. | Response of established human breast tumors to vaccination with mammaglobin-A cDNA | |
| Jochems et al. | Identification and characterization of agonist epitopes of the MUC1-C oncoprotein | |
| Jafferji et al. | Adoptive T-cell therapy for solid malignancies | |
| Sasada et al. | Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines | |
| Valilou et al. | Tumor antigens | |
| Weber | Peptide vaccines for cancer | |
| Acres et al. | Targeted immunotherapy designed to treat MUC1-expressing solid tumour | |
| Okada et al. | Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis | |
| Sonpavde et al. | Recent advances in immunotherapy for the treatment of prostate cancer |